› Forums › General Melanoma Community › Breaking Research News from ASCO
- This topic has 3 replies, 1 voice, and was last updated 11 years, 6 months ago by W..
- Post
-
- June 2, 2013 at 5:38 pm
A number of important melanoma research updates have emerged from the American Society of Clinical Oncology (ASCO) annual meeting, including a report on Sunday, June 2 about the combination of ipilimumab and nivolumab. Both drugs are designed to engage the immune system in fighting melanoma. In the study, the combined drugs helped shrink tumors in 38% of patients overall. One arm of the study generated a 52% response rate in patients. The study has been published online in the New England Journal of Medicine.A number of important melanoma research updates have emerged from the American Society of Clinical Oncology (ASCO) annual meeting, including a report on Sunday, June 2 about the combination of ipilimumab and nivolumab. Both drugs are designed to engage the immune system in fighting melanoma. In the study, the combined drugs helped shrink tumors in 38% of patients overall. One arm of the study generated a 52% response rate in patients. The study has been published online in the New England Journal of Medicine.
Viewing 2 reply threads
- Replies
Viewing 2 reply threads
- You must be logged in to reply to this topic.